BRIEF-Vaxxas initiates research collaboration with Merck

Oct 9 (Reuters) - Vaxxas:

* Vaxxas initiates program with Merck to optimize delivery of next generation vaccines utilizing novel mechanism for immune system activation

* Says the collaboration will evaluate Vaxxas' proprietary nanopatch platform

* Says granted Merck an exclusive license for nanopatch platform for commercial production of an undisclosed vaccine candidate

* Says under the agreement, Merck will pay an upfront fee and will provide funding to vaxxas to conduct research

* Says will also be eligible to receive additional payments from Merck

* Source text

((Bangalore Newsroom; +1 646 223 8780))